NASDAQ:BLFS BioLife Solutions (BLFS) Stock Price, News & Analysis $23.79 -0.94 (-3.80%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$23.12▼$24.8050-Day Range$19.19▼$26.5252-Week Range$8.92▼$26.73Volume362,177 shsAverage Volume386,486 shsMarket Capitalization$1.10 billionP/E RatioN/ADividend YieldN/APrice Target$26.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioLife Solutions alerts: Email Address BioLife Solutions MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside10.1% Upside$26.20 Price TargetShort InterestBearish8.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.33Based on 4 Articles This WeekInsider TradingSelling Shares$264,890 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.37) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.26 out of 5 starsMedical Sector745th out of 910 stocksElectromedical Equipment Industry16th out of 22 stocks 2.5 Analyst's Opinion Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioLife Solutions has only been the subject of 3 research reports in the past 90 days.Read more about BioLife Solutions' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.51% of the outstanding shares of BioLife Solutions have been sold short.Short Interest Ratio / Days to CoverBioLife Solutions has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in BioLife Solutions has recently decreased by 2.49%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBioLife Solutions does not currently pay a dividend.Dividend GrowthBioLife Solutions does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLFS. Previous Next 3.5 News and Social Media Coverage News SentimentBioLife Solutions has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioLife Solutions this week, compared to 3 articles on an average week.Search Interest15 people have searched for BLFS on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $264,890.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of BioLife Solutions is held by insiders.Percentage Held by Institutions93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioLife Solutions' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLife Solutions are expected to grow in the coming year, from ($0.37) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLife Solutions is -16.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLife Solutions is -16.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLife Solutions has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about BioLife Solutions' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About BioLife Solutions Stock (NASDAQ:BLFS)BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Read More BLFS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLFS Stock News HeadlinesSeptember 5 at 2:30 PM | finance.yahoo.comInvesting in BioLife Solutions (NASDAQ:BLFS) a year ago would have delivered you a 78% gainAugust 28, 2024 | americanbankingnews.comBioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Rating of "Buy" from AnalystsSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 28, 2024 | americanbankingnews.comBioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Rating of "Buy" by BrokeragesAugust 22, 2024 | sg.finance.yahoo.comBioLife Solutions Inc (BJX1.DU)August 20, 2024 | seekingalpha.comBioLife Is Cleaning ShipAugust 19, 2024 | msn.comBioLife Solutions (BLFS) Surpassed Revenue and Earnings-Per-Share Expectations in Q2August 16, 2024 | finance.yahoo.comBioLife Solutions, Inc. (NASDAQ:BLFS): Is Breakeven Near?September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioLife Solutions Amid Strong Market Position and Positive Financial OutlookAugust 9, 2024 | finanznachrichten.deBioLife Solutions, Inc.: BioLife Solutions Reports Second Quarter 2024 Financial ResultsAugust 9, 2024 | seekingalpha.comBioLife Solutions, Inc. (BLFS) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | markets.businessinsider.comBuy Rating Justified by BioLife Solutions’ Strong Financial Position and Growth ProspectsAugust 8, 2024 | prnewswire.comBioLife Solutions Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | msn.comIs BioLife Solutions, Inc. (BLFS) the Best Organ Transplant and Diagnosis Stock to Buy Now?July 26, 2024 | finance.yahoo.comIs It Time To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?July 25, 2024 | prnewswire.comBioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024May 29, 2024 | prnewswire.comBioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in VancouverSee More Headlines Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:BLFS CUSIPN/A CIK834365 Webwww.biolifesolutions.com Phone(425) 402-1400Fax425-402-1433Employees440Year FoundedN/APrice Target and Rating Average Stock Price Target$26.20 High Stock Price Target$30.00 Low Stock Price Target$22.00 Potential Upside/Downside+10.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,430,000.00 Net Margins-59.88% Pretax Margin-51.03% Return on Equity-10.75% Return on Assets-8.89% Debt Debt-to-Equity Ratio0.04 Current Ratio2.86 Quick Ratio1.81 Sales & Book Value Annual Sales$139.96 million Price / Sales7.83 Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / Book3.41Miscellaneous Outstanding Shares46,069,000Free Float45,055,000Market Cap$1.10 billion OptionableOptionable Beta1.85 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Roderick de Greef (Age 64)CEO & Chairman Comp: $1.63MMr. Troy Wichterman (Age 39)Chief Financial Officer Comp: $485.2kMs. Karen Foster (Age 64)Chief Quality & Operations Officer Comp: $395.2kDr. Aby J. Mathew Ph.D. (Age 52)Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer Comp: $448.2kMr. Todd Berard (Age 55)Chief Marketing Officer Comp: $286.49kMs. Sarah Aebersold J.D. (Age 47)Chief Human Resources Officer Mr. Garrie Richardson B.Sc. (Age 51)M.B.A., Chief Revenue Officer More ExecutivesKey CompetitorsNatus MedicalNASDAQ:NTUSZynexNASDAQ:ZYXIOutset MedicalNASDAQ:OMPROCEPT BioRoboticsNASDAQ:PRCTAxonicsNASDAQ:AXNXView All CompetitorsInsiders & InstitutionsMillennium Management LLCSold 903,853 shares on 8/15/2024Ownership: 2.191%Meros Investment Management LPBought 6,586 shares on 8/15/2024Ownership: 0.868%The Manufacturers Life Insurance Company Bought 753 shares on 8/15/2024Ownership: 0.030%Public Sector Pension Investment BoardBought 7,902 shares on 8/14/2024Ownership: 0.174%Marshall Wace LLPBought 10,695 shares on 8/14/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions BLFS Stock Analysis - Frequently Asked Questions How have BLFS shares performed this year? BioLife Solutions' stock was trading at $16.25 at the beginning of the year. Since then, BLFS shares have increased by 46.4% and is now trading at $23.79. View the best growth stocks for 2024 here. How were BioLife Solutions' earnings last quarter? BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings results on Thursday, August, 8th. The medical equipment provider reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.08. The medical equipment provider had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative net margin of 59.88% and a negative trailing twelve-month return on equity of 10.75%. What is Mike Rice's approval rating as BioLife Solutions' CEO? 14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend. Who are BioLife Solutions' major shareholders? BioLife Solutions' top institutional shareholders include Fred Alger Management LLC (3.43%), William Blair Investment Management LLC (3.41%), Millennium Management LLC (2.19%) and Dimensional Fund Advisors LP (1.73%). Insiders that own company stock include Casdin Partners Master Fund, L, Greef Roderick De, Michael Rice, Aby J Mathew, Karen A Foster, Troy Wichterman, Todd Berard, Geraint Phillips, Sarah Aebersold, Marcus Schulz, Amy Duross and Joseph C Schick. View institutional ownership trends. How do I buy shares of BioLife Solutions? Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE) and Rigel Pharmaceuticals (RIGL). This page (NASDAQ:BLFS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLife Solutions, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLife Solutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.